The Alexandria Real Estate Equities-backed oncology therapy developer is floating in the middle of its range to raise $82.5m in its initial public offering.
US-based exosome therapeutics developer Codiak BioSciences will go public today in an $82.5m initial public offering representing an exit for life science real estate investment trust Alexandria Real Estate Equities.
The company is issuing 5.5 million shares on the Nasdaq Global Market priced at $15.00 each, in the middle of the offering’s $14 to $16 range.
Codiak is developing medicines to treat diseases with high unmet medical need, including cancer, by using extracellular cell vesicles known as exosomes as…
